2. Autophagy Apoptosis
  3. Autophagy Mitophagy Apoptosis
  4. Liensinine

Liensinine 

Cat. No.: HY-N0484 Purity: 99.97%
COA Handling Instructions

Liensinine is an autophagy/mitophagy inhibitor. Liensinine, a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn, has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc.

For research use only. We do not sell to patients.

Liensinine Chemical Structure

Liensinine Chemical Structure

CAS No. : 2586-96-1

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
5 mg USD 60 In-stock
10 mg USD 95 In-stock
25 mg USD 200 In-stock
50 mg USD 320 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Other Forms of Liensinine:

Liensinine Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Liensinine is an autophagy/mitophagy inhibitor. Liensinine, a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn, has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc[1].

In Vivo

Liensinine (oral gavage, 100 or 200 mg/kg, daily, 10 weeks) can effectively treat periodontitis, similar to metronidazole-type drugs, and has a certain dose-dependent[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: KM mice[2]
Dosage: 100 mg/kg, 200 mg/kg
Administration: oral gavage, daily, 10 weeks
Result: Reduced the gingival index and increased the SOD levels, the CAT, GSH-Px levels and decreased the NO, MDA, and ET levels compared to the control group.
Animal Model: Institute of Cancer Research (ICR) mice (male, 20-22 g)[3]
Dosage:
Administration: 5 mg/kg by oral administration; 1 mg/kg by intravenous administration
Result: The pharmacokinetic parameters of Liensinine in mice
Parameters po (5 mg/kg) iv (1 mg/kg)
AUC(0-t) (ng/mL*h) 18.8 ± 2.7 211.2 ± 54.9
AUC(0-∞) (ng/mL*h) 19.1 ± 2.8 227.9 ± 60.1
MRT(0-t)( h) 3.2 ± 0.4 2.6 ± 0.5
MRT(0-∞) (h) 3.4 ± 0.5 3.5 ± 0.9
t1/2z (h) 1.9 ± 0.2 3.8 ± 0.8
CLz/F (L/h/kg) 266.0 ± 41.3 4.7 ± 1.2
Vz/F (L/kg) 708.5 ± 79.9 25.9 ± 11.0
Cmax (ng/mL) 5.3 ± 0.2 169.5 ± 53.5
Clinical Trial
Molecular Weight

610.74

Appearance

Solid

Formula

C37H42N2O6
CAS No.
SMILES

OC1=CC=C(C[C@H]2N(C)CCC3=C2C=C(OC)C(OC)=C3)C=C1OC4=CC5=C(C=C4OC)CCN(C)[C@@H]5CC6=CC=C(O)C=C6
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (81.87 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.6374 mL 8.1868 mL 16.3736 mL
5 mM 0.3275 mL 1.6374 mL 3.2747 mL
10 mM 0.1637 mL 0.8187 mL 1.6374 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 20 mg/mL (32.75 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

  • 2.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (3.41 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (3.41 mM); Clear solution

  • 4.

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.08 mg/mL (3.41 mM); Clear solution

*All of the co-solvents are available by MedChemExpress (MCE).
Purity & Documentation

Purity: 99.97%

COA (250 KB) HNMR (304 KB) LCMS (87 KB) OR (214 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Liensinine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

Liensinine2586-96-1AutophagyMitophagyApoptosisMitochondrial AutophagyapoptosisautophagyautophagicstressbreastcancerDNM1LlysosomemitochondrialfissionRAB7AInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Liensinine
Cat. No.:
HY-N0484
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.